Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries.

Greece’s Health Minister Thanos Plevris announced plans to sue Novartis over what he alleges are illegal practices. The scandal has been playing out for several years, with Novartis alleged to have paid Greek public officials and health care providers to increase prescriptions for the company’s drugs and maintain higher prices.

In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus.

Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.

In the company’s financial results for 2021 released on May 11, Takeda announced the decision to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome. Additionally, Takeda is collaborating with JCR Pharmaceuticals in another therapeutic attempt for the condition.

Johnson & Johnson on May 11 appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of 2023.

Twist Bioscience and Astellas have entered into a research collaboration and exclusive option license agreement to identify potential therapeutic antibodies which would help to reduce tumor microenvironment-mediated immunosuppression.

Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.

Janssen terminated a seven-year-old vaccine collaboration with Bavarian Nordic. The two companies partnered in 2015 to develop potential vaccines against the hepatitis B virus and human papillomaviruses.